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ABSTRACT
Introduction: While guidelines stronglyrecommend dexamethasone in critical COVID-19, the
optimal threshold to initiate corticosteroids in
non-critically ill patients with COVID-19
remains unclear. Using data from a state-wide
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COVID-19 registry, we evaluated the effectiveness of early corticosteroids for preventing
clinical deterioration among non-critically ill
patients hospitalized for COVID-19 and receiving non-invasive oxygen therapy.
Methods: This was a target trial using observational data from patients hospitalized for COVID19 at 39 hospitals participating in the MICOVID19 registry between March 16, 2020 and
August 24, 2020. We studied the impact of corticosteroids initiated within 2 calendar days of
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hospitalization (‘‘early steroids’’) versus no early
steroids among non-ICU patients with laboratoryconfirmed SARS-CoV2 receiving non-invasive
supplemental oxygen therapy. Our primary outcome was a composite of in-hospital mortality,
transfer to intensive care, and receipt of invasive
mechanical ventilation. We used inverse probability of treatment weighting (IPTW) and
propensity score-weighted regression to measure
the association of early steroids and outcomes.
Results: Among 1002 patients meeting study
criteria, 231 (23.1%) received early steroids.
After IPTW, to balance potential confounders
between the treatment groups, early steroids
were not associated with a decrease in the
composite outcome (aOR 1.1, 95%CI 0.8–1.6) or
in any components of the primary outcome.
Conclusion: We found no evidence that early
corticosteroid therapy prevents clinical deterioration among hospitalized non-critically ill
COVID-19 patients receiving non-invasive
oxygen therapy. Further studies are needed to
determine the optimal threshold for initiating
corticosteroids in this population.
Keywords: Corticosteroid therapy; COVID-19
therapeutics; SARS-COV2; Viral infections
Key Summary Points
While corticosteroids are proven beneficial
in critical COVID-19, the role of early
corticosteroids in non-critically ill
hospitalized COVID-19 patients remains
unclear.
Using data from a state-wide COVID-19
registry, we studied the impact of ‘‘early’’
corticosteroids (started within 2 days of
hospitalization) versus ‘‘no early’’ steroids
in preventing clinical deterioration
among non-critically ill hospitalized
COVID-19 patients.
In our cohort of 1002 COVID-19 patients
receiving non-invasive oxygen therapy
across 39 hospitals, early steroids were not
associated with a decrease in-hospital
mortality, transfer to intensive care, or
intubation.
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INTRODUCTION
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to
cause substantial morbidity and mortality
around the world [1]. Corticosteroids quickly
emerged as a potential treatment option in
COVID-19 because of their immunomodulatory
effects and potential benefits in ARDS and septic
shock from other etiologies [2, 3].
While initial guidance regarding corticosteroids was inconsistent, corticosteroids became
standard-of-care for patients with severe
COVID-19 in June 2020, after results of the
RECOVERY randomized clinical trial showed a
mortality reduction in oxygen-treated patients,
with the greatest benefit for patients receiving
invasive mechanical ventilation [4]. Following
the RECOVERY trial press release, other steroid
trials halted randomization, and the available
trial data were pooled through the World
Health Organization’s Rapid Evidence Appraisal
for COVID-19 Therapies prospective metaanalysis-which confirmed the benefit of steroids
in critically ill patients [4, 5]. All major practice
guidelines were subsequently updated to recommend corticosteroids in COVID-19 patients
receiving supplemental oxygen, with the
strongest recommendation for patients receiving invasive mechanical ventilation [6–8].
While corticosteroids are clearly beneficial in
critical COVID-19, the precise threshold of illness above which corticosteroids are indicated
remains unclear. In particular, it is unclear
whether corticosteroids are indicated in noncritically ill patients who are receiving low-flow
oxygen therapy [9–11]. Most trials of early
steroids in COVID-19 focused either exclusively
on critically ill patients [5, 12–14] or included
patients with heterogenous respiratory support
[4], ranging from nasal canula oxygen to noninvasive ventilation, due to their pragmatic
design.
Assessing the benefit of steroids in non-critically ill patients is important because corticosteroid therapy is known to have several
potential side effects, including hyperglycemia
and fluid retention. Pertinent to COVID-19,
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corticosteroids may also prolong viral shedding,
as seen in viral pneumonias from severe acute
respiratory syndrome (SARS) and Middle East
respiratory syndrome [15–17]. Finally, in
observational studies of severe pneumonia
caused by influenza viruses, corticosteroid
therapy has been associated with worse clinical
outcomes, including secondary bacterial infection and death [18]. Collectively, these data
highlight the need for additional studies to
evaluate the benefit of corticosteroids in noncritically ill patients hospitalized with COVID19 [19, 20].
Therefore, using data from a state-wide,
multi-hospital COVID-19 registry, we evaluated
the impact of early corticosteroid use on preventing clinical deterioration in patients hospitalized with COVID-19 and receiving noninvasive oxygen therapy. We hypothesized that
early corticosteroid treatment would be associated with a reduced mortality, transfer to
intensive care, or receipt of invasive mechanical
ventilation.

METHODS
Data Source: the MI-COVID19 registry
We utilized data from the MI-COVID 19 registry, a multi-hospital Continuous Quality Initiative sponsored by Blue Cross Blue Shield of
Michigan and Blue Care Network, which aims
to improve care for hospitalized patients with
COVID-19. Over 40 Michigan hospitals voluntarily participate in MI-COVID-19 [21]. Trained
abstractors at each hospital collected detailed
data on adult patients hospitalized with
COVID-19 using a structured data collection
template. Patient characteristics, including
demographics, medical history, comorbidities,
physical findings, laboratory results, imaging
studies, and medications, were abstracted
directly from medical records. The term ‘‘corticosteroid’’ was harmonized across abstractors
and across sites to be systemic (enteral or
intravenous) corticosteroid therapy. Data
abstracters collected data on the dose, route,
type, and duration of systemic steroids directly
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from medication administration records in the
electronic chart.
For hospitals unable to abstract all COVID-19
hospitalizations because of high volumes, hospitalizations were sorted by day of admission
(e.g., Monday–Sunday) and, for each day, a
pseudo-random number (minute of hospital
discharge) was used to select a sample of
patients for abstraction.
Cohort Inclusion/Exclusion Criteria
We identified all patients hospitalized with
laboratory-confirmed SARS-CoV-2 infection
(between March 16, 2020 and August 24, 2020)
from MI-COVID-19 registry hospitals, who
received supplemental oxygen during day 1
and/or day 2 of hospitalization, remained alive,
and were in a non-ICU hospital location. We
excluded patients with: (1) length of hospitalization\3 days; (2) no supplemental oxygen
therapy during day 1 and/or day 2; (3) receipt of
invasive mechanical ventilation or ICU level of
care during day 1 and/or day 2; (4) admission
via inter-hospital transfer; (5) who were pregnant; (6) transitioned to hospice within 3 h of
hospital admission; or (7) discharged against
medical advice. The goal of the inclusion and
exclusion criteria was to emulate a target trial of
corticosteroid therapy [22]. Because hospital
days 1 and 2 were used for eligibility and strategy assignment, we ensured that no patients
either met the study outcome (death, ICU, or
invasive mechanical ventilation) or were ineligible for the study outcome (i.e., discharged
alive from hospital) during days 1 or 2.
Treatment Assignment
Patients meeting study eligibility criteria were
categorized into two treatment groups: early
corticosteroids (treatment) and no early corticosteroids (comparison). Patients who received
intravenous or oral dexamethasone, prednisone, methylprednisolone, or hydrocortisone
within 2 days of arrival to the hospital or
emergency department comprised the early
steroid group. The comparison group included
all patients who received no corticosteroids
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during the first 2 days of hospitalization. Prehospital corticosteroid use and corticosteroids
use after day 2 were not considered in the study
group assignment.
Study Outcomes
The primary outcome was clinical deterioration,
defined as a composite of hospital mortality,
ICU transfer, or receipt of invasive mechanical
ventilation. Secondary outcomes included
individual components of the composite outcome and hospital length of stay C 7 days.
Subgroups
We examined the primary and secondary outcomes in the overall cohort and for several
predefined subgroups by age (\70 vs.
C 70 years), duration of symptoms prior to
hospitalization (\7 days vs. C 7 days) and
maximum oxygen requirement during hospital
days 1 and 2 (FiO2 \40% vs. FiO2 C 40%).
Statistical Analysis
All variables were summarized with standard
descriptive statistics, including mean and standard deviation (SD). Categorical variables were
summarized using percentages. Propensity score
regression adjustment was used to reduce
selection bias. We used an inverse probability of
treatment weighting (IPTW) approach based on
patients’ propensity score (i.e., patients’ predicted probability of receiving corticosteroids
given their baseline covariates) to balance the
differences in baseline variables between treatment groups [23].
A non-parsimonious multivariable logistic
regression model was constructed to estimate
each patient’s propensity score. Variables of the
propensity score (PS) model were prespecified
before outcome analyses, and included: (1)
patient demographics {age, gender, race, body
mass index}; (2) co-morbidities {cardiac, pulmonary, diabetes, cancer}; (3) clinical symptoms on hospital presentation {fever, dyspnea};
(4) vital signs during day 1 and 2 of hospitalization {blood pressure, respiratory rate, highest
oxygen support}; and (5) laboratory and
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radiology features on hospital presentation
{creatinine, white blood cell count, and presence of imaging abnormalities}. These covariates were chosen based on clinical experience,
review of literature, and data available in the
COVID-19 registry [24]. We adjusted for date of
admission (measured in half-month epochs) to
account for temporal trends in treatment
approach (e.g., hydroxychloroquine) and outcomes independent of corticosteroids.
Group distributions were evaluated to
determine if the groups were comparable and
the IPTW was calculated and normalized. After
IPTW, the treatment and comparison groups
were similar except for the slight differences in
the proportion of admissions occurring during
the June 2020 epochs.
We converted different steroids into maximum prednisone equivalents to reduce heterogeneity and to create a standardized framework
for comparing steroid dose and duration
between treatment and control groups (Steroid
Conversion Calculator; MDCalc).
Characteristics between the unadjusted and
adjusted groups were compared using t tests for
continuous variables and Pearson’s chi-squared
tests for categorical variables. Propensity scoreweighted regression models were then fitted to
compare primary and secondary outcomes
between groups. Odds ratios with 95% confidence intervals (OR, 95% CI) were reported, and
overall two-sided alpha-level of 0.05 was used to
determine statistical significance. Data were
analyzed using SAS software v.9.4 (SAS Institute,
Cary, NC, USA).
IRB Statement
MI-COVID-19 was deemed to be quality
improvement work and received the designation of non-regulated by the University of
Michigan institutional review board. Each hospital participating in the Mi-COVID19 initiative
is required to have a signed Data Use Agreement
with the Coordinating Center for the collaborative. The data submitted is a limited dataset
and is therefore sharable in an aggregated and
de-identified format.
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Fig. 1 CONSORT diagram showing the enrollment of subjects, their allocation to treatment, and how they were analyzed
in the study

RESULTS
Among 2217 hospitalizations for COVID-19 in
the MI-COVID-19 registry during the study
period, 1215 were excluded, leaving 1002
patients in our trial emulation (Fig. 1). Of 1002
eligible patients, 231 (23.1%) were treated with
corticosteroids within 2 days of presentation
(treatment group), while 771 (76.9%) were not
(comparison group). Totals of 12 patients in the
treatment and 55 patients in the control group
had missing data needed for propensity score
calculation and were excluded, leaving 935
patients for analysis.
Unadjusted patient characteristics are shown
in Supplementary Table 1. Of the patients in the

treatment group, 33% were black compared to
44% in the comparison group. Patients in the
treatment group were also more likely to have
heart disease or chronic lung disease and to have
received corticosteroids prior to hospitalization.
Totals of 162 (70.1%) patients in the treatment
group and 342 (44.4%) in the comparison group
received high-intensity supplemental oxygen
therapy during the baseline/enrollment period
[i.e., oxygen via nasal prongs or mask at C 6 LPM
or C 40%FIO2; heated high flow nasal cannula
(HHFNC); or non-invasive positive pressure
ventilation (NIPPV)]. After inverse probability
weighting, baseline demographic and clinical
characteristics were not different between the
treatment and comparison groups (Table 1).
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Table 1 Characteristics of treatment versus comparison groups after inverse probability weighting
Treatment (early
steroids) (n 5 219)

Comparison (no early
steroids) (n 5 716)

p value

Age, mean (SD)

66.62 (14.40)

65.56 (17.14)

0.41

BMI, mean (SD)

31.29 (8.55)

31.33 (8.37)

0.94

Female

50.4%

47.7%

0.48

Race: Black

39.3%

42.2%

0.44

Self-pay insurance

3.0%

2.4%

0.67

Prior steroids/immunosuppressive therapy

11.6%

11.5%

0.96

Diabetes- complicated

12.5%

11.1%

0.57

Heart disease

40.6%

39.6%

0.79

Chronic lung disease

33.0%

28.3%

0.18

Cancer

9.5%

8.7%

0.70

Moderate/severe kidney disease

27.5%

25.8%

0.63

Patient characteristics and comorbidities

Vitals, symptoms, and laboratory values during baseline/enrollment period
Fever ([100.4 [F])

36.5%

36.9%

0.91

Dyspnea/shortness of breath

80.4%

78.2%

0.48

Elevated respiratory rate (C 20)

94.2%

91.5%

0.19

Decreased systolic blood pressure (\100 mmHg)

26.0%

27.3%

0.70

High supplemental oxygen support ﬁrst 2 days (low
ﬂow NC C 6 l or FiO2 C 40%, HHFNC, NIPPV)

56.8%

50.2%

0.09

Max. creatinine, mean (SD)

1.68 (4.94)

1.98 (7.17)

0.57

Max. white blood cell (WBC), mean (SD)

7.82 (3.37)

7.86 (6.42)

0.94

Imaging abnormalities on CXR or chest CT

39.6%

37.3%

0.53

Early March, late March admission

3.3%, 30.3%

0.7%, 43.9%

0.003,\0.001

Early April, late April admission

42.0%, 12.8%

28.4%, 13.9%

\0.001, 0.67

Early May, late May admission

6.2%, 2.9%

6.1%, 3.0%

0.95, 0.89

Early June, late June admission

0.1%, 1.8%

3.3%, 0.3%

0.01, 0.01

Early July, late July admission

0.2%, 0.3%

0.2%, 0.3%

0.92, 0.89

Early August admission

0.2%

0.0%

0.21

Date of hospital admission
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In the treatment group, the median time
between symptom onset and start of corticosteroid therapy was 5 days. A total of 224 (97%)
patients in the treatment group received prednisone or methylprednisolone, while 14 (6.1%)
patients were treated with dexamethasone.
During days with any corticosteroid treatment,
patients in the treatment group received a
median prednisone-equivalent of 75 mg/day,
with a median treatment duration of 4 days. A
total of 129 (16.7%) patients in the comparison
group also received IV or oral steroids after day
2 of hospitalization. Supplemental Table 2 provides additional information on steroid use in
treatment versus comparison groups.
The composite outcome of in-hospital mortality, transfer to the ICU, or receipt of MV
occurred 28% in the treatment and 24% in the
comparison group. In our IPTW multivariable
model, early corticosteroids were not associated
with decreased odds of the composite outcome
(OR 1.1, 95% CI 0.8–1.6) in the overall cohort
(Table 2), nor in any of the pre-specified subgroups defined by age, baseline FIO2 requirement, or duration of symptoms (Table 3). Early
corticosteroids were also not associated with a
decrease in any of the individual measures of
the primary outcomes of in-hospital mortality
(OR 1.3, 95% CI 0.9–1.9), transfer to ICU level
of care (OR 1.3, 95% CI 0.8–1.9), or receipt of

invasive mechanical ventilation (OR 1.7, 95%
CI 1.1–1.7). Early steroids were also not associated with a decreased odds of hospitalization
length of stay C 7 days (OR 0.9, 95% CI 0.6–1.2)
(Table 2).

DISCUSSION
In this multi-center observational target trial
emulation assessing the impact of early corticosteroid therapy in non-critically ill patients
with COVID-19, we found no evidence that
early corticosteroids prevent clinical deterioration. Specifically, we were unable to detect an
association between early corticosteroids and
reduced mortality, ICU transfer, or receipt of
invasive mechanical ventilation.
Recommendations for the use of corticosteroids in non-critically ill hospitalized COVID19 patients requiring oxygen therapy are largely
based on data from the RECOVERY trial, a large,
multi-hospital, randomized, open-label trial
performed in the United Kingdom. This trial
compared hospitalized patients who received
up to 10 days of dexamethasone to those who
received the standard of care. There was no
difference in mortality with dexamethasone
among patients who did not require oxygen at
enrollment (RR 1.2; 95% CI 0.9–1.6). In

Table 2 Association of early steroid treatment with primary and secondary outcomes
Treatment
Comparison (no
(early steroids) early steroids)

Adjusted
odds ratio

95%
conﬁdence
interval

62/219 (28%)

173/716 (24%)

1.1

(0.8, 1.6)

In-hospital mortality

48 (22%)

123 (17%)

1.3

(0.9, 1.9)

Transfer to ICU level of care

32 (15%)

101 (14%)

1.3

(0.8, 1.9)

Mechanical ventilation

25 (11%)

64 (9%)

1.7

(1.1, 2.7)

93/219 (42%)

317/716 (44%)

0.9

(0.6, 1.2)

Primary outcome
Composite of in-hospital mortality, mechanical
ventilation, and transfer to ICU level of care
Secondary outcomes
Individual components of primary outcome

Length of stay C 7 days

Odds ratios were generated from inverse probability of treatment weighted multivariable logistic regression models
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Table 3 Rate of primary composite outcome of death, mechanical ventilation and ICU transfer by subgroup

All Patients

Treatment

Comparison

Adjusted odds ratio

95% conﬁdence interval

61/217 (28%)

169/703 (24%)

1.1

(0.8, 1.6)

Duration of symptoms before hospitalization
\7 days

43/130 (33%)

120/370 (32%)

1.0

(0.7, 1.6)

C 7 days

18/87 (21%)

49/333 (15%)

1.2

(0.6, 2.2)

\70 years

23/117 (20%)

66/436 (15%)

1.3

(0.8, 2.2)

C 70 years

39/101 (39%)

107/280 (38%)

1.1

(0.6, 1.8)

Age at hospitalization

Max. supplemental oxygen during baseline/enrollment period
1–6 L (\40%) low-ﬂow oxygen
All other oxygen

17/66 (26%)

87/407 (21%)

1.2

(0.7, 2.1)

45/152 (30%)

86/309 (28%)

1.0

(0.7, 1.7)

contrast, among patients who received supplemental oxygen (nasal canula, heated high-flow
oxygen, and non-invasive positive pressure
ventilation), but were not mechanically ventilated at enrollment, 23.3.% of patients in the
dexamethasone arm died within 28 days compared to 26.2% of patients in the standard of
care arm (RR 0.8; 95% CI 0.7–0.9). However,
because detailed data on the mode and amount
of oxygen therapy were not collected, it is
impossible to tease out the threshold at which
corticosteroids are indicated from the RECOVERY trial.
The National Institute of Health COVID
guidelines suggest dexamethasone can be
withheld for hospitalized patients who require
‘‘minimal amounts of supplemental oxygen, but
be given (either alone or in combination with
remdesivir) in patients who require ‘‘increasing
amounts of supplemental oxygen’’ [8]. Hence,
we wanted to focus specifically on hospitalized
COVID-19 patients requiring supplemental
oxygen therapy to assess whether early use of
steroids would be beneficial, and to identify the
threshold of illness at which steroids would be
helpful. Our study results are consistent with
other observational studies that showed no
difference in risk of intubation or mortality
between non-critically ill hospitalized patients
who received versus those that did not receive
corticosteroids [11, 15, 25, 26].

There are many potential reasons for the
discrepancy between our results and the findings of the oxygen-treated subgroup in
RECOVERY. First, our study focused on a
potentially less severely ill hospitalized population than the oxygen-treated patients in
RECOVERY. Only 7% of patients in our treatment group received HHFNC therapy and none
received NIPPV. Second, the RECOVERY trial
specifically evaluated dexamethasone 6 mg
orally or intravenously for up to 10 days or until
hospital discharge, whichever came first. While
the pooled meta-analysis from WHO included
patients that received dexamethasone, hydrocortisone,
and
methylprednisolone,
the
RECOVERY trial contributed to 59% of patients
in this meta-analysis. Many of the trials evaluating alternative glucocorticoids were terminated early after release of results from the
RECOVERY trial. Thus, the evidence to support
the use of hydrocortisone OR 0.7 (95% CI
0.4–1.1; P = 0.1) and methylprednisolone OR
0.9 (95% CI 0.3–2.9; P = 0.9) is not as robust as
for dexamethasone OR 0.6 (95% CI 0.5–0.8;
P\0.001) [5]. Our study mostly evaluated
methylprednisolone and prednisone (97% of all
steroids used in the treatment group), and
notably the average dose of methylprednisolone
(75 mg in the treatment group) was twice as
high as the equivalent dose of dexamethasone
recommended in guidelines. Further, the
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median duration of steroids in our study was
4 days in the early steroid group, which was
significantly shorter than the recommended
duration of 10 days. This may suggest the
importance of the choice, dose, and duration of
steroids used in COVID-19 to blunt the
inflammatory response consistent with results
from other studies [27, 28].
Our study should be considered in the context of several limitations. First, it is an observational study in which the decision to
administer corticosteroids was at the discretion
of the treating clinicians and influenced by
local hospital guidelines. We were careful to
adhere to best practices for target trial emulation, and did not consider corticosteroid use
after day 2 in the study group assignment. Thus,
16.7% patients in the comparison group
received IV or oral steroids after day 2, which
may have blunted the difference in mortality
between treatment and comparison groups.
However, because these patients likely received
late corticosteroids in response to clinical deterioration, excluding them would have introduced bias. Instead, we used IPTW to balance
potential confounders between the treatment
and comparison groups. Similar designs have
been used in large COVID-19 trials assessing
vaccine efficacy and efficacy of COVID 19
therapeutics [29, 30]. While this approach was
successful at balancing the a priori confounders
(including pre-existing co-morbidities and use
of systemic steroids pre-hospitalization), we
cannot exclude the possibility of unmeasured
confounding. Second, due to small sample sizes,
we were unable to evaluate specific steroid regimens, and hence used maximum prednisone
equivalents
to
standardize
comparisons
between the treatment and control groups.
Similarly, inhaled corticosteroid use was out of
the scope of this study. Third, while we did not
balance on actual bacterial co-infection based
on cultures, we balanced on clinical signs and
symptoms suggestive of co-infection (fever,
dyspnea, vital signs, WBC, imaging abnormalities) to ensure that our treated and untreated
populations had equivalent likelihoods of bacterial co-infection. Few patients in our cohort
presented with bacterial co-infection, as reported in a separate study [31]. Finally, this study
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occurred during the initial U.S. surge, when
there was a relatively lower threshold to initiate
invasive mechanical ventilation, due to concerns for aerosolization of SARS-CoV-2 with
high-flow oxygen, and significant variation in
treatments among our hospitals [32]. However,
we ensured that the treatment groups were
contemporaneous (and therefore subject to
similar thresholds for ICU transfer and initiation of invasive mechanical ventilation) by
including half-month epoch as a co-variate in
our model.

CONCLUSIONS
Using data from a multihospital, state-wide
registry, we found no association between early
corticosteroid therapy and the composite outcome of in-hospital mortality, transfer to the
ICU, and/or receipt of invasive mechanical
ventilation in patients hospitalized for COVID19 and requiring supplemental non-invasive
oxygen therapy. Our study highlights the need
for additional RCTs to determine the optimal
timing, dose, and duration for corticosteroid
therapy in non-invasive, mechanically ventilated patients with COVID-19.
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